Company intelligence / Profile preview

Verndari, Inc.

Napa, California, United Statesnexusmods.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Verndari’s VaxiPatch™ has demonstrated thermostability and higher efficacy than traditional vaccine delivery in pre-clinical studies. The company is developing a rapid-response, room-temperature-stable single-dose vaccination kit that does not require needles or refrigeration.[1][4] Their technology aims to simplify administration and improve global access to vaccines.

Therapeutic areas: Infectious Diseases
Modalities: Vaccines (including mRNA vaccines)Intradermal microarray delivery technology[1][2][5]
Industry: Biotech

Drug pipeline

3 assets

influenza B (Colorado/06/2017) vaccine antigen

Approved

2 more assets in the full pipeline.

Request access →

Partnerships

Biomedical Advanced Research and Development Authority (BARDA) [5]

Beyond the preview

Go deeper on Verndari, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verndari, Inc..

Explore the full profile